Ideas
Buy select Korean chip equipment beneficiaries.
The first trading day pointed to a semiconductor capex cycle. Rather than buying every equipment and materials name indiscriminately, Kang favors selected suppliers that can benefit from HBM4, advanced packaging, and thinner wafers; names such as Wonik IPS, Hanmi Semiconductor, DB HiTek, Dongjin Semicam, and TES are being rewarded, but the market will later separate true beneficiaries from beta-driven laggards. He suggests filling exposure toward 50% in Samsung/SK hynix plus equipment and materials.
NAVER lacks valuation-justifying AI edge.
NAVER's valuation is not justified relative to Samsung/SK hynix because its Korean-language AI opportunity caps the addressable market, search is losing usage to Google, YouTube, and global AI assistants, and server/AI/B2B initiatives have not yet shown credible execution. PBR is near the market average, but without a clear NAVER-specific identity or earnings inflection, the stock remains unattractive.
Kakao expensive with slow AI execution.
Kang remains uncomfortable with Kakao: AI progress is slow and it is taking the easy path of ads in open chat, while valuation is expensive at about 40x P/E and 2.3x PBR versus NAVER's 1.2x and the market's roughly 1.22x PBR. The company has not shown enough execution to justify the multiple.
Korean biotech too speculative to hold.
Kang views Korean biotech as too speculative and momentum-driven: the market often prices near-100% success even though US FDA Phase 3 success rates are around 11%, clinical costs are large, and rallies allow biotech companies to raise capital from shareholders. He prefers to avoid the sector as a fundamental hold.
Celltrion relatively attractive within biotech.
Within biotech, Celltrion is relatively attractive because it has a cash-generating business, a US factory, and improving margin mix expectations, unlike speculative development-stage biotech. However, price competition, new biosimilar entrants, capacity expansion, and legacy inventory issues remain risks.
Trade Korean defense/aerospace on momentum.
Kang is fundamentally positive on Korean defense and aerospace because US-China rivalry, the Ukraine war, and local conflicts favor Korea's cost-effective and increasingly proven weapons; in aerospace, Korean companies are gaining US market recognition, supporting price-to-sales multiples even before large earnings. However, many names are already expensive, so he treats the broader group as a momentum trading opportunity rather than a buy-and-hold.
Hanwha Aerospace best defense/aerospace hold.
Hanwha Aerospace is the preferred defense/aerospace name because it is like the sector's Samsung Electronics: it has stakes in affiliates such as Hanwha Systems and Hanwha Ocean, and its forward valuation is relatively reasonable at under 20x earnings, so it can be held while other defense/aerospace names are only for trading.
SK Square cheap high-beta SK hynix proxy.
SK Square is a high-beta 2.3x holding company with a large stake in SK hynix. Its price-to-NAV is only about 0.54x, a 66% discount versus the usual holding-company discount near 60%, so it remains undervalued despite the rally; rising foreign ownership and a tight share supply can amplify upside. Kang says it is worth considering while price-to-NAV is below 0.6x.
Korean brokers benefit from market volume.
Kang favors Korean securities and brokerage stocks because a rising KOSPI and record trading volume improve earnings, and additional drivers include retail inflows, KOSDAQ activation, and M&A or deal activity in a rate-cut cycle. He sees securities as a listed proxy for market upside, preferable to banks in this phase.
Korean banks unattractive in rate cuts.
In a rate-cut cycle, Korean banks are less attractive because net interest margin compresses and loan growth is unlikely to expand enough to offset it, especially with real-estate lending constrained. Kang says banks are not interesting in this cycle.
KOSPI upside toward 4,500 before rebalancing.
Kang expects the Korean market to keep grinding higher because 2026-27 ROE estimates have been revised up to 12.3%, Samsung's preliminary results could lift estimates further, and foreign investors still need to buy at least KRW 10tn to return to prior ownership levels. Valuation can stretch to forward PBR 1.35-1.40x, equivalent to KOSPI around 4,500, so investors should stay invested and only rebalance or take profits near that zone; long-term investors can accumulate on dips. Catalysts include Samsung guidance and MSCI developed-market watchlist news, with Korea likely decoupling from the US in the first half.
Foreign buying still needed in chip leaders.
Foreign ownership of Samsung Electronics and SK hynix is still only in the 52-53% range, below the prior peak near 56%, implying foreigners must buy much more. This foreign buying, combined with rising earnings estimates, should support the core Korean semiconductor leaders.
This 815 Money Talk (815머니톡) video, published January 06, 2026,
features Kang Gwan-woo
discussing Korean semiconductor equipment/materials, 042700.KS, WONIK IPS, 000990.KS, 005290.KQ, 095610.KQ, 035420.KS, 035720.KS, Korean biotech/pharma, 068270.KS, Korean defense/aerospace, 012450.KS, 402340.KS, Korean securities/brokerage sector, KBE, EWY, 005930.KS, 000660.KS.
12 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Kang Gwan-woo
· Tickers:
Korean semiconductor equipment/materials,
042700.KS,
WONIK IPS,
000990.KS,
005290.KQ,
095610.KQ,
035420.KS,
035720.KS,
Korean biotech/pharma,
068270.KS,
Korean defense/aerospace,
012450.KS,
402340.KS,
Korean securities/brokerage sector,
KBE,
EWY,
005930.KS,
000660.KS
